Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options

被引：3
|
作者：
Schmidt, Andrew [1 ]
Azad, Arun [2 ]
Goh, Jeffrey [3 ,4 ]
Harris, Carole [5 ,6 ]
Joshua, Anthony M. [7 ]
Weickhardt, Andrew [8 ]
Krieger, Laurence [9 ]
机构：
[1] Liz Plummer Canc Ctr, Cairns, Qld, Australia
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Royal Brisbane & Womens Hosp, Butterfield St, Herston, Qld, Australia
[4] Univ Queensland, St Lucia, Qld, Australia
[5] St George Hosp, Kogarah, NSW, Australia
[6] Sutherland Clin Sch UNSW, Kogarah, NSW, Australia
[7] Kinghorn Canc Ctr, Darlinghurst, NSW, Australia
[8] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia
[9] Royal North Shore Hosp, Northern Canc Inst, Reserve Rd, St Leonards, NSW, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 15卷
关键词：
immuno-oncology; renal cell carcinoma; VEGF tyrosine kinase inhibitors; INTERFERON-ALPHA; PREEXISTING AUTOIMMUNE; OPEN-LABEL; EVEROLIMUS; SUNITINIB; EFFICACY; SURVIVAL; CANCER; NEPHRECTOMY; LENVATINIB;
D O I：
10.1111/ajco.13289
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Vascular endothelial growth factor receptor tyrosine kinase inhibitors have provided an effective standard of care for the treatment of metastatic clear cell renal cell carcinoma (mRCC). Survival is prolonged with emergence of modern immuno-oncology combination regimens. Prognostic risk assessment is essential for choosing between these therapies to determine the most appropriate first line treatment option, with selection based on International Metastatic RCC Database Consortium Risk Category. We review the current subsidized first line treatments for mRCC in Australia and consider the evidence for treatment selection and sequencing.
引用
收藏
页码：3 / 10
页数：8
相关论文
共 50 条
  • [31] Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma
    Labriola, Matthew K.
    Batich, Kristen A.
    Zhu, Jason
    McNamara, Megan A.
    Harrison, Michael R.
    Armstrong, Andrew J.
    George, Daniel J.
    Zhang, Tian
    CLINICAL GENITOURINARY CANCER, 2019, 17 (03) : E513 - E521
  • [32] Defining risk status in the first-line treatment of metastatic renal cell carcinoma
    Schmidinger, Manuela
    Zielinski, Christoph C.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (07) : 961 - 968
  • [33] First-line treatment of metastatic renal cell carcinoma: current standard of care
    Marszalek, Martin
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 (04) : 334 - 338
  • [34] Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
    Tassinari, Elisa
    Mollica, Veronica
    Nuvola, Giacomo
    Marchetti, Andrea
    Rosellini, Matteo
    Massari, Francesco
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 1945 - 1960
  • [35] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Vazquez, Sergio
    Leon, Luis
    Fernandez, Ovidio
    Lazaro, Martin
    Grande, Enrique
    Aparicio, Luis
    ADVANCES IN THERAPY, 2012, 29 (03) : 202 - 217
  • [36] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
    Sergio Vázquez
    Luis León
    Ovidio Fernández
    Martín Lázaro
    Enrique Grande
    Luis Aparicio
    Advances in Therapy, 2012, 29 : 202 - 217
  • [37] A systematic review and network meta-analysis of first-line treatment options in patients metastatic renal cell carcinoma
    Bin Riaz, Irbaz
    Ryu, Alexander J.
    Yao, Yuan
    Siddiqi, Rabbia
    Mathew, Jessey
    Sipra, Qurat Ul Ain Riaz
    Zahoor, Haris
    Wang, Zhen
    Murad, M. Hassan
    Pagliaro, Lance C.
    Costello, Brian Addis
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [38] New approaches to first-line treatment of advanced renal cell carcinoma
    George, Daniel J.
    Lee, Chung-Han
    Heng, Daniel
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [39] Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma
    Benedict, Agnes
    Figlin, Robert A.
    Sandstrom, Per
    Harmenberg, Ulrika
    Ullen, Anders
    Charbonneau, Claudie
    Sandin, Rickard
    Remak, Edit
    Hariharan, Subramanian
    Negrier, Sylvie
    BJU INTERNATIONAL, 2011, 108 (05) : 665 - 672
  • [40] First-line therapy in advanced renal cell carcinoma
    Rexer, H.
    Steiner, Th.
    Grunwald, V.
    UROLOGE, 2017, 56 (04): : 509 - 511
12345